| Name | Title | Contact Details |
|---|
Lexicon Pharmaceuticals, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Spring, TX. To find more information about Lexicon Pharmaceuticals, Inc, please visit www.lexpharma.com
Lutherwood is a Waterloo, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Interim HealthCare Inc., founded in 1966, is a leading national franchisor of home care, hospice and healthcare staffing. It is part of Caring Brands International which also includes UK-based Bluebird Care and Australia-based Just Better Care, both well-known franchise brands in their countries. With more than 530 franchise locations in seven countries Caring Brands International is a global health care leader. Interim HealthCare in the United States is unique in combining the commitment of local ownership with the support of a national organization that develops innovative programs and quality standards that improve the delivery of service. Franchisees employ nurses, therapists, aides, companions and other healthcare professionals who provide 25 million hours of home care service to 190,000 people each year, meeting a variety of home health, senior care, hospice, palliative care, pediatric care and healthcare staffing needs.
Southwest Missouri Office on Aging is a Springfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.